hyperpolarized Xenon gas
Phase 1Small molecule
hyperpolarized Xenon gas is one of 82 small molecule programs targeting Lung Disease. It is currently in Phase 1.
2
Indications
5
Total Trials
2
Active Trials
81
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
74 competitors in Lung Disease
#DrugCompanyPhaseTrials
1Cipro
BayerApproved
Zithromax
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Approved
Precedex
MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.
Approved
Viagra
VViatris Specialty LLC
Approved
Kenalog
BBassett Healthcare
Approved
Versed
CConrado Roberto Hoffmann Filho
Approved
Proair HFA
GGlaxo Dba Glaxosmithkline
Approved
Rituxan
RochePhase 3
Kalydeco
Vertex PharmaceuticalsPhase 3
Biaxin
AbbViePhase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
CLE1 trial
Airway Clearance Therapy on Hyperpolarized 129Xenon and MRI
Completed·—··NCT03593434·20 enrolled
Lung Transplantation1 trial
Imaging and Understanding BOS in Lung Transplantation
Completed·—··NCT02316392·6 enrolled
Children1 trial
Use of Hyperpolarized Xenon Gas for Lung Imaging in Children and Adults
Recruiting·—·Phase 1/2·NCT02272049·300 enrolled
Imaging1 trial
Use of Hyperpolarized 129Xe MR Lung Imaging in Adults for Calibration
Recruiting·—·Phase 1/2·NCT02316379·100 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for hyperpolarized Xenon gas. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details